A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00401765 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: CNTO 328
DRUG: Docetaxel

Sponsor

Centocor, Inc.